Evidence map›Paper›PMID 41482348›Full record

ArticleCancer genomics & proteomics

Optimizing Liquid Biopsy: Spike-In Panel Approach for ctDNA Copy Number Variation Analysis.

Hyunji Kim, Byoung Mok Kim, Jinho Kim, Soo Hyun Seo, Sang Mee Hwang, Kyoung Un Park

Abstract read
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Hyunji KimDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Byoung Mok KimDepartment of Genomic Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
Jinho KimDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Soo Hyun SeoDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea; shseo81@gmail.com.
Sang Mee HwangDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Kyoung Un ParkDepartment of Laboratory Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimCirculating tumor DNA (ctDNA) testing has emerged as a minimally invasive tool for precision oncology, enabling dynamic monitoring of tumor burden and treatment response. However, commercial ctDNA NGS assays often omit clinically important oncogenes, limiting accurate assessment of copy-number variation (CNV). Amplifications of MATERIALS AND

methodsSpike-in targets were designed with KAPA Target Enrichment Custom Designs and integrated into the Avenio panel. Reference materials (Horizon Structural Multiplex cfDNA Standard, 5% (

resultsMean exon coverage was 698.5 for

conclusionIncorporation of a spike-in panel into the Avenio ctDNA assay enabled reliable detection of high-level

Indexed as

Biomarkers, TumorCirculating Tumor DNADNA Copy Number VariationsHigh-Throughput Nucleotide SequencingHumansLiquid BiopsyN-Myc Proto-Oncogene ProteinBiomarkers, TumorCirculating Tumor DNAMYCN protein, humanN-Myc Proto-Oncogene ProteinCirculating tumor DNAcopy number variationliquid biopsyMYCMYCNnext-generation sequencingspike-in panel

Identifiers

PMID41482348
PMCPMC12758656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.